Literature DB >> 19273224

MDM2 and MDM4 splicing: an integral part of the cancer spliceome.

Selvi Jeyaraj1, Dennis M O'Brien, Dawn S Chandler.   

Abstract

MDM2 and MDM4, the murine double minute proteins, are oncogenes that function as important regulators of various proteins. One fundamental role for these proteins is regulation of the tumor suppressor, p53. Precise regulation of p53 is vital for coordinated malignant suppression and cell survival. Alternative splice forms of MDM2 as well as MDM4 have been associated with various cancers. Indeed, UV irradiation triggers alternative splicing of both MDM2 and MDM4. Coordinated alternative splicing in response to cellular stress or in cancerous cells regulates the posttranscriptional expression of these two genes and likely others. This concert of stress responsive mRNAs comprises the cancer spliceome and provides a fingerprint of coordinated alternative splicing in these aberrant cells. Although various transcripts have been described for both proteins, here we provide a precise catalog of the alternatively spliced transcripts of both genes and the cancers with which they are associated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273224     DOI: 10.2741/3402

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  19 in total

1.  Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage.

Authors:  Daniel J Colacurcio; Alyssa Yeager; Dennis L Kolson; Kelly L Jordan-Sciutto; Cagla Akay
Journal:  Mol Cell Neurosci       Date:  2013-10-12       Impact factor: 4.314

2.  ROS and p53 in regulation of UVB-induced HDM2 alternative splicing.

Authors:  Lingying Tong; Shiyong Wu
Journal:  Photochem Photobiol       Date:  2014-07-26       Impact factor: 3.421

3.  Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.

Authors:  Stella Koutros; Fredrick R Schumacher; Richard B Hayes; Jing Ma; Wen-Yi Huang; Demetrius Albanes; Federico Canzian; Stephen J Chanock; E David Crawford; W Ryan Diver; Heather Spencer Feigelson; Edward Giovanucci; Christopher A Haiman; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Peter Kraft; Loïc Le Marchand; Elio Riboli; Afshan Siddiq; Mier J Stampfer; Daniel O Stram; Gilles Thomas; Ruth C Travis; Michael J Thun; Meredith Yeager; Sonja I Berndt
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

4.  MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network.

Authors:  Rana Elkholi; Ioana Abraham-Enachescu; Andrew P Trotta; Camila Rubio-Patiño; Jarvier N Mohammed; Mark P A Luna-Vargas; Jesse D Gelles; Joshua R Kaminetsky; Madhavika N Serasinghe; Cindy Zou; Sumaira Ali; Gavin P McStay; Cathie M Pfleger; Jerry Edward Chipuk
Journal:  Mol Cell       Date:  2019-03-14       Impact factor: 17.970

5.  Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells.

Authors:  Matthew T Balmer; Ryan D Katz; Si Liao; James S Goodwine; Susannah Gal
Journal:  Cancer Biol Ther       Date:  2014-05-06       Impact factor: 4.742

6.  Splicing up mdm2 for cancer proteome diversity.

Authors:  Danielle R Okoro; Melissa Rosso; Jill Bargonetti
Journal:  Genes Cancer       Date:  2012-03

7.  PDIP38 is translocated to the spliceosomes/nuclear speckles in response to UV-induced DNA damage and is required for UV-induced alternative splicing of MDM2.

Authors:  Agnes Wong; Sufang Zhang; Dana Mordue; Joseph M Wu; Zhongtao Zhang; Zbigniew Darzynkiewicz; Ernest Y C Lee; Marietta Y W T Lee
Journal:  Cell Cycle       Date:  2013-09-03       Impact factor: 4.534

Review 8.  The spliceosome as a target of novel antitumour drugs.

Authors:  Sophie Bonnal; Luisa Vigevani; Juan Valcárcel
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

Review 9.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

10.  Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage.

Authors:  Daniel F Comiskey; Aishwarya G Jacob; Ravi K Singh; Aixa S Tapia-Santos; Dawn S Chandler
Journal:  Nucleic Acids Res       Date:  2015-04-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.